

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
03 November 2022 (03.11.2022)

WIPO | PCT

(10) International Publication Number

WO 2022/232411 A9

(51) International Patent Classification:

C12N 15/113 (2010.01) A61K 31/7125 (2006.01)
A61K 31/712 (2006.01) A61P 25/28 (2006.01)

(21) International Application Number:

PCT/US2022/026760

(22) International Filing Date:

28 April 2022 (28.04.2022)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/181,023	28 April 2021 (28.04.2021)	US
63/320,651	16 March 2022 (16.03.2022)	US
63/334,496	25 April 2022 (25.04.2022)	US

(71) Applicant: EISAI R&D MANGEMENT CO., LTD.

[JP/JP]; 6-10 Koishikawa, 4-Chome, Bunkyo-ku, Tokyo
112-8088 (JP).

(72) Inventors: VATHIPADIEKAL, Vinod; 35 Cam-

bridgepark Dr., Suite 200, Cambridge, Massachusetts
02140 (US). MITASEV, Branko; 35 Cambridgepark Dr.,

Suite 200, Cambridge, Massachusetts 02140 (US). EAS-
LEY-NEAL, Courtney; 35 Cambridgepark Dr., Suite 200,
Cambridge, Massachusetts 02140 (US). CHOI, Hyeon
Wook; 35 Cambridgepark Dr., Suite 200, Cambridge,
Massachusetts 02140 (US). FANG, Frank; 35 Cam-
bridgepark Dr., Suite 200, Cambridge, Massachusetts
02140 (US). WANG, John; 35 Cambridgepark Dr., Suite
200, Cambridge, Massachusetts 02140 (US). VEMU-
LA, Praveen; 35 Cambridgepark Dr., Suite 200, Cam-
bridge, Massachusetts 02140 (US). LEE, Jung Hwa; 35
Cambridgepark Dr., Suite 200, Cambridge, Massachusetts
02140 (US).

(74) Agent: HEMMELGARN, Benjamin T.; FINNEGAN,
HENDERSON, FARABOW, GARRETT & DUNNER,
LLP, 901 New York Avenue, NW, Washington, District of
Columbia 20001-4413 (US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IR, IS, IT, JM, JO, JP, KE, KG, KH,

(54) Title: ANTISENSE OLIGONUCLEOTIDES AND THEIR USE FOR TREATMENT OF NEURODEGENERATIVE
DISORDERS




FIG. 1

(57) Abstract: Novel antisense oligonucleotides that induce Exon-2 skipping in the *CD33* gene during pre-mRNA splicing, and their use in the treatment of a neurodegenerative disease, such as Alzheimer's disease, are disclosed.

[Continued on next page]

KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA,
MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI,
NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU,
RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM,
TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM,
ZW.

- (84) Designated States** (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))

(88) Date of publication of the international search report:

01 December 2022 (01.12.2022)

Date of publication of the revised international search report:

16 March 2023 (16.03.2023)

(15) Information about Correction:

see Notice of 16 March 2023 (16.03.2023)